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A system-level framework of complex microbe-microbe and host-microbe chemical 
cross-talk would help elucidate the role of our gut microbiota in health and disease.  
Here we report a literature-curated interspecies network of the human gut microbiota, 
called NJS16.  This is an extensive data resource composed of ~570 microbial species 
and 3 human cell types metabolically interacting through >4,400 small-molecule 
transport and macromolecule degradation events.  Based on the contents of our 
network, we develop a mathematical approach to elucidate representative microbial 
and metabolic features of the gut microbial community in a given population, such as 
a disease cohort.  Applying this strategy to microbiome data from type 2 diabetes 
patients reveals a context-specific infrastructure of the gut microbial ecosystem, core 
microbial entities with large metabolic influence, and frequently-produced metabolic 
compounds that might indicate relevant community metabolic processes.  Our 
network presents a foundation towards integrative investigations of community-scale 
microbial activities within the human gut. 
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The microbial habitat within the human intestine is the site of an extraordinarily complex and dynamic 
symbiosis.  Central to the structure and evolution of the resident gut microbial community (gut 
microbiota) are the various interactions between microbes and with their chemical environment1,2.  
Colonic microbes survive and grow by consuming diet-derived and host-derived chemical compounds, 
as well as metabolic byproducts excreted by other microbes3.  Undigested dietary macromolecules 
and host-derived substrates (such as mucin) are broken down by microbial species, and then the 
solubilized molecules become available to other members of the community as public goods for 
uptake.  Furthermore, inherent microbial activities involving the import of metabolic nutrients and 
export of metabolic byproducts give rise to both competition for resources and cooperative 
relationships, such as metabolic cross-feeding, among resident microorganisms in the gut 
environment4.  In addition, the interactions of the gut microbiota with the host are increasingly 
recognized to impact many aspects of human health and disease5,6.  For example, microbial 
fermentation products such as short-chain fatty acids (SCFAs) have active roles in normal host 
physiology, as energy sources for colonocytes, regulators of gene expression and cell differentiation, 
and anti-inflammatory agents7,8.  On the other hand, some metabolic byproducts can be toxic, 
impairing host tissue function and promoting the onset and progression of disease9.  Taken together, 
numerous microbe-microbe and microbe-host interconnections serve as the basis of a complex 
ecological network in the human gut.   
   Recent advances in sequencing technologies and metagenomics have revealed associations 
between the abundance of taxonomic groups (or their genetic repertoire) and a number of disorders, 
including obesity, inflammatory bowel disease, colorectal cancer, and type 2 diabetes10-13.  Such 
descriptive, profiling investigations offer important insights into taxonomic and functional variations 
relevant to host phenotypes; yet, a mechanistic and comprehensive understanding of those observed 
results remains elusive.  Notwithstanding the importance of individual microbial species, the 
consequent impact of the microbiota on the host would be largely attributed to the collective activities 
of numerous microbial species and metabolic compounds, thoroughly interlinked by network 
relationships.  This realization calls for an integrative network-based approach for a system-level 
understanding of the human gut microbiota14,15.  If available, a comprehensive map of molecular 
interactions between microbial species could be used to integrate the vast collection of previous 
findings into a global network context. 
   In the microbiome research field, a common practice to build a microbial interaction network has 
been based on statistical correlations of taxa abundances across samples16,17.  However, correlation-
based inference networks hardly provide explicit mechanistic details behind the identified correlations.  
Another existing approach is to map the entire metabolic pathways by the direct annotation of 
metagenome sequences18,19.  Despite the advantage of evaluating the metabolic potential of the 
community in its entirety, this method does not segregate biochemical reactions to those of different 
species, preventing its application for the analysis of interspecies interactions.  Furthermore, based on 
the information of different metabolic networks of individual microbial species, there are previous 
works that have modeled diverse interspecies interactions explicitly mediated by imported or exported 
metabolites20,21.  Yet, these works have relied on error-prone automated identification of transportable 
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(importable or exportable) metabolites, and therefore are possibly incomplete or inaccurate to some 
extent.  Despite ongoing computational efforts to describe microbial interactions using biologically 
realistic (manually curated constraint-based or simplified kinetic) metabolic models22-24, most of these 
models have not yet reached the scale of diversity in the gut community, which typically comprises 
hundreds of different microbial species (it is noteworthy that this scale of microbial diversity has been 
recently covered by semi-automatically generated, constraint-based metabolic models25). 
   Here we present a global interspecies metabolic interaction network of the human gut microbiota, 
NJS16.  The information upon which the network architecture stands is primarily from literature-based 
annotations.  Therefore, our network maps the landscape of existing biological knowledge and 
curated experimental data.  To demonstrate the utility of our network, we developed a mathematical 
framework for analyzing gut microbial communities in a given population, such as a cohort of type 2 
diabetes (T2D) patients.  Recent studies have indicated that, as a prominent environmental factor, 
alterations in the gut microbiota contribute to the pathology of this disease12,26.  Combined with fecal 
metagenomic information from T2D patients12, our network analysis reveals a community-scale 
infrastructure of metabolic influence within the T2D gut ecosystem. 
 
Results 
 
Metabolite transport network of the human gut microbiota 
We aimed to construct a community-level network composed of microbial species populating the 
human gut (Fig. 1).  To construct our network, we started by applying a phylogenetic analysis tool on 
previously published, shotgun metagenomic sequencing data from fecal samples of Chinese 
individuals12.  Further details of the microbiome data and of the taxonomic profiling method are 
provided in Methods and Supplementary Data 1.  Next, we extensively searched the published 
literature for all annotated, mainly experimental, information that describes the small-molecule 
metabolites (e.g., monosaccharides, disaccharides, SCFAs, vitamins, and gases), which are 
transported into, and/or out of, the microbial species identified in the microbiome samples (see 
Supplementary Data 2 for bibliography of literature references).  To complement our list of annotated 
microbe-metabolite associations, we included macromolecule degradation reactions, i.e., microbes 
and the macromolecules (e.g., cellulose, hemicellulose, inulin, starch, and mucin) they are known to 
degrade, as well as the resulting degradation products (e.g., D-glucose and cellobiose from cellulose; 
N-acetylglucosamine, N-acetylneuraminate, L-fucose, and sulfate from mucin).  Although tissue cells 
of the human host are not physically a part of the gut microbiota, in this study we view them as a 
functional extension of the bacterial and archaeal community residing in the colon, because host cells 
either can directly affect, or can be affected by, microbial metabolism.  The specific host cells that we 
considered were the colonocyte (cell-type specific metabolic model from Recon 2)27, the goblet cell 
(for mucin secretion), and the hepatocyte (for glycine- or taurine-conjugated bile acid export).  Lastly, 
we linked all microbes and host cells to their associated metabolites and macromolecules into a 
comprehensive reference map of human gut microbiota and chemical compound relationships.  More 
specifically, a community member and a chemical compound are then connected by a (directed) link if 
the organism can import and/or export the metabolite, or degrade the macromolecule (see Methods 
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and Fig. 2 for further details of our network construction approach and the assessment of its possible 
biases, respectively). 
   We present NJS16, a literature-curated community-level network of the human gut microbiota 
organized through metabolite transport (Fig. 1).  Our network is a compilation of 4,483 annotated 
transport or degradation reactions (from about 400 research articles, reviews, and textbooks) between 
244 metabolic compounds (229 small molecules and 15 macromolecules) and 570 microbial species 
and human cell types (511 bacteria, 56 archaea, and 3 host cells) (see Supplementary Data 2 for 
information on all nodes and edges in NJS16, on the associations between macromolecules and their 
breakdown products, and on which microbial species have been previously well studied regarding 
their relationship to the human gut).  To investigate the inherent network topology of NJS16, we 
calculated the number of metabolites imported or exported by each microbial species.  Each species 
in NJS16 imports 5.1 and exports 3.9 metabolites on average (median 3 metabolites for both cases), 
and the probability that a given species imports (or exports) k metabolites follows an exponential 
distribution P(k) ∝ e−rk (r ≈ 0.2 and 0.4 for the import and export cases, respectively; see Figs 3a, b).  
The most promiscuous species is Bacteroides thetaiotaomicron, which imports 34 and exports 29 
metabolites.  Conversely, for each metabolite, we calculated the number of species importing or 
exporting that metabolite.  The probability that a given metabolite is exported by k species follows a 
power-law distribution P(k) ∝ k−γ (γ ≈ 1.6), which is much broader than the previous exponential fits; 
such a broad distribution is also observed from imported metabolites (Figs 3c, d).  Specifically, 
glucose and acetate are the most frequent substrate and product, respectively, and are imported by 
118 (20.8% of the total species) and exported by 251 species (44.3% of the total species).  In contrast, 
an average metabolite is imported by 13.4 and exported by 20.7 species (median 7 and 4 species, 
respectively).  Collectively, these results indicate that metabolites are highly uneven in terms of their 
use by species. 
   Microbes compete against each other for the utilization of available substrates (e.g., carbon, 
nitrogen, and phosphorus sources) in the human gut.  In our network, this competition is especially a 
common feature among groups of microbes that share common metabolic and physiological 
characteristics, such as acetogens and sulfate-reducing bacteria [interestingly, our network and 
microbiome data show that the similarity in two species’ nutritional profiles is positively correlated with 
the species’ co-occurrence (ρ = 0.29 and P = 0.02), in agreement with a previous claim20 when the 
same measures were applied].  Cooperative relationships are also present, in the form of (i) 
interspecies cross-feeding, wherein a metabolic byproduct of one microbe is a nutrient of another (see 
each Fig. 1 inset that shows microbes surrounding a particular metabolite); and (ii) macromolecule 
degradation, wherein a microbe, via its ability to degrade macromolecules and thereby release the 
degradation products into the microenvironment as public goods, provides nutrients not only for itself, 
but also for other community members.  For example, lactate produced by Bifidobacterium, 
Enterococcus, and Lactobacillus species is imported by lactate-consumers, such as Anaerostipes 
caccae and Bilophila wadsworthia.  Macromolecule degraders, such as those that target 
hemicellulose (e.g., Prevotella ruminicola), can provide the degradation products (e.g., D-arabinose, 
D-galactose, and xylooligosaccharides) to themselves, as well as to nearby microbes. 
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Figure 1. Global landscape of the human gut microbiota organized through metabolite 
transport.  Overview of NJS16.  The import of nutrients (yellow directed edges) and export of 
metabolic byproducts (blue directed edges) comprise the organizational basis of the gut microbial 
community.  Microbes of common metabolic function are clustered together as functionally similar 
groups (large colored nodes).  Within the microbial community, competition exists for the consumption 
of the same metabolites (small black nodes); cooperative relationships also occur, in the form of (i) 
interspecies cross-feeding, as exemplified in the figure insets, and (ii) macromolecule degradation, 
wherein a microbe degrades macromolecules in its extracellular space (red directed edges), thereby 
releasing degradation products (gray directed edges stemming from macromolecule nodes) as public 
goods.  As a functional extension of the bacterial and archaeal community residing in the colon, 
human host cells either can directly affect, or can be affected by, microbial metabolism.  Host cell 
types in the network are: (i) colonocytes, which absorb nutrients produced by certain microbes, (ii) 
goblet cells, which secrete complex mucus glycoproteins for mucin-degrading microbes, and (iii) 
hepatocytes, which, although not part of colonic tissue, secrete conjugated bile acids that are 
consumed by microbes. 
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Figure 2. Comparison of transportable metabolites from NJS16 and those inferred from 
existing databases.  (a) For each microbial species (each data point), the horizontal and vertical 
axes represent the number of its transportable metabolites from NJS16 and that inferred from the 
Kyoto Encyclopedia of Genes and Genomes (KEGG)69, respectively.  The latter was obtained by 
counting the species’ KEGG compounds that are common to any of the entire transportable 
metabolites in NJS16.  This KEGG-based estimation would result in many false positives; however, 
the KEGG information might be relatively free of the literature bias that NJS16 harbors, and thus can 
possibly serve as a more unbiased counterpart to NJS16.  Most data points are located over the gray 
diagonal, indicating that most species have more transportable metabolites according to KEGG than 
to NJS16.  The presence of species with few metabolites in NJS16 can be, at least in part, attributed 
to literature bias with false negatives in the species’ metabolites.  (b) The vertical axis represents the 
distribution of the probability P(k) that a given microbial species has k metabolites (horizontal axis) in 
its defined growth media whose information is from the Known Media Database (KOMODO)70.  We 
considered common species between NJS16 and KOMODO (only when found to have defined media 
information), and counted their media components that are common to any of the transportable 
metabolites in NJS16.  For a given species, the number of such media components may possibly 
approximate the number of its importable metabolites.  Compared to Fig. 3a, which is derived from 
NJS16, (b) exhibits peaks at large metabolite numbers on the horizontal axis, possibly indicating false 
negatives in NJS16’s importable metabolites.  Yet, given KOMODO’s low coverage of microbial 
species in NJS16 (9.2%), and given that microbes may not necessarily import all compounds in their 
defined growth media, our results warrant a cautious interpretation. 
 
 
Figure 3. Network structural properties of NJS16.  In (a) and (b), the vertical axis represents the 
distribution of the probability P(k) that a given microbial species imports (a) or exports (b) k 
metabolites on the horizontal axis.  In (c) and (d), the vertical axis represents the distribution of the 
probability P(k) that a given metabolite is imported (c) or exported (d) by k species on the horizontal 
axis.  (a) and (b) exhibit an exponential distribution P(k) ∝ e−rk with r ≈ 0.2 for (a) and r ≈ 0.4 for (b).  
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(c) and (d) show more right-skewed distributions than (a) and (b).  (d) shows a power-law distribution 
P(k) ∝ k−γ with γ ≈ 1.6. 
 
 
As such, host cells are also involved in the cooperative metabolic relationships within the gut 
microbiota: colonocytes can absorb metabolites produced by microbes (e.g., SCFAs, amino acids, 
and vitamins); goblet cells secrete complex mucus glycoproteins as part of the intestinal mucosal 
layer, which are a target for mucin-degrading microbes (e.g., Akkermansia muciniphila and B. 
thetaiotaomicron); and hepatocytes export glycine- or taurine-conjugated bile acids, which eventually 
flow into the intestine and are taken up by bile-acid consuming microbes (e.g., Bacteroides fragilis 
and Clostridium perfringens).  As clearly seen in these examples, metabolite-driven cooperative 
relationships are pervasively seen throughout the entire network (Fig. 1).  Using NJS16, we can now 
begin to explore the organizing characteristics of global microbial metabolic activities in the human gut 
environment. 
 
Context-specific microbial metabolic influence network 
Herein, we demonstrate the potential of our global metabolite transport network of the gut microbiota 
for elucidating context-specific, community-level features.  We developed a mathematical framework 
and applied it on the aforementioned Chinese microbiome samples, which were previously obtained 
from T2D patients and non-diabetic controls12.  In particular, we undertook the analysis of this data 
with an aim to identify the most representative microbial and metabolic features of T2D gut 
microbiota, and to gain insight into relevant microbe-microbe and microbe-host relationships.   
   Recent studies have shown that gut microbiota composition and its functional traits can vary 
according to socio-demographic and environmental factors, such as ethnicity, gender, age, and diet28-
30.  These factors can also have a profound impact towards diseases such as T2D31.  This indicates 
that comparative microbiome analyses (e.g., case vs. control) should be conducted in well-
characterized cohort populations controlled for sources of confounding variation.  Therefore, for 
subsequent analyses, we selected T2D and non-diabetic control microbiome samples from a 
demographic cohort characterized as male, mid-age, and normal weight.  This particular cohort was 
chosen because it has the largest sample size among all cohorts, as well as comparable sample 
numbers in both phenotypes (control n = 21; T2D n = 11).  Because of a possible confounding effect 
on the gut microbiome by an oral anti-diabetic medication32, we used T2D samples from only 
metformin-untreated patients (Methods).  For this male, mid-age, and normal weight cohort, we then 
found microbial entities differentially abundant or scarce in T2D (Methods).  Here, a microbial entity 
represents a single microbial species or a group of multiple microbial species; a group pertains to 
microbial species of either a genus or a metabolic clique, which is defined here as a group of species 
that import, export, or degrade the same metabolite or macromolecule (e.g., glucose importers, 
butyrate exporters, or cellulose degraders).  A total list of relevant microbial entities is presented in 
Supplementary Data 3. 
   Next, we applied NJS16 as a reference map to build the community structure of microbial entities 
abundant or scarce in T2D, and to understand how they metabolically influence each other.  This 
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network, which we will call henceforth the microbial metabolic influence network (MIN), is based on 
actual microbial relative abundance information from the relevant T2D and control microbiome 
samples, i.e., context-specific abundance information.  A brief description of how we can construct 
these context-specific microbial MINs is as follows: in complex, microbial ecosystems, a microbial 
entity can provide nutrients to another entity via interspecies cross-feeding of metabolic byproducts 
and/or release of macromolecule degradation products.  This positive impact may potentially promote 
microbial growth.  In contrast, a microbial entity can limit another entity’s access to nutrients via 
competition for the same metabolites.  This negative impact may potentially inhibit microbial growth.  
Based on the combination of such positive and negative effects, we can leverage information from 
NJS16 to formulate and quantify the net metabolic influence of a microbial entity i on another entity j 
(Wij).  If each entity i or j is a single species but not a group of multiple species, Wij is estimated as 
∑ ∑∑
=








−≈
1
c
c
p
pcjkg
k
m
mkm
iki
m
mkm
iki
ij gn
gn
gn
gnW α , 
where ni characterizes entity i’s abundance, k denotes the metabolites consumed by entity j, gikp(c) =1 
if entity i produces (consumes) metabolite k, or otherwise, gikp(c) =0, and α is a constant.  Full details of 
Wij, including its formulation, the incorporation of macromolecule degradation, extension to the case 
where entity i or j is a multi-species group, and the determination of α, are described in Methods and 
Supplementary Methods.  Overall, if a microbial entity i is found to have a higher growth-promoting 
capability than a growth-inhibiting capability towards another microbial entity j, then Wij > 0, and we 
classify this interaction as having a net positive metabolic influence; if there is a higher growth-
inhibiting capability than a growth-promoting capability, then Wij < 0, and we classify this interaction as 
having a net negative metabolic influence.  This approach allows us to construct a community-level 
network of positive and negative metabolic influences between pairs of microbial entities differentially 
abundant or scarce in T2D (codes are available in Supplementary Software).  Furthermore, we 
include in these networks cross-feeding interactions between microbes and the host (Methods and 
Supplementary Methods), along with their corresponding metabolites. 
   In Fig. 4, we show the MIN composed of microbial entities associated with a male, mid-age, and 
normal weight cohort.  It features the interplay of positive and negative metabolic influences among 
125 microbial entities.  116 of these 125 are differentially abundant in T2D compared to control, while 
9 are differentially scarce.  As mentioned above, one major way a microbial entity exerts a net positive 
metabolic influence is through its ability to release macromolecule degradation products for 
consumers of those public goods.  For instance, Acidothermus cellulolyticus can degrade cellulose in 
this MIN.  Cellulose degradation supplies D-glucose, cellobiose, and cellulose oligosaccharides to the 
microbial community.  As another example, A. muciniphila in MIN participates in mucin degradation, 
providing the degradation products to the microbial community.  The other major way a microbial 
entity can have a net positive metabolic influence is through cross-feeding of exported metabolites.  
For example, a member of the Propionibacterium genus produces riboflavin for Lactobacillus 
delbrueckii in the MIN. 
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Figure 4. Metabolic influence network among the most representative microbial entities of T2D 
in a given demographic cohort.  We identified community-wide metabolic influence relationships 
between microbial entities differentially abundant in T2D (gold nodes) and in non-diabetic control 
(blue nodes) in a male, mid-age, and normal weight cohort.  Specifically, the networks are 
characterized by positive (gray directed edge) and negative (red directed edge) metabolic influences 
between pairs of microbial entities.  Furthermore, entities that are highly influential—by exerting a 
metabolic influence towards a substantial number of microbial entities—are depicted as network 
influencers (nodes with orange background.  See also Fig. 5a).  The number of species that compose 
each microbial group is shown in parentheses next to the respective group’s name.  Microbe-to-host 
(colonocyte) cross-feeding relationships that were predicted to be of representative importance are 
shown in green directed edges, with some examples of the corresponding metabolites.  
Macromolecule degradation by individual microbial species, or by multiple species in a microbial 
group, is exemplified through purple edges.  Full lists of microbial entities and compounds in the 
networks are too dense for direct visualization, and therefore only a part of them are presented.  Full 
details of this network are available in Supplementary Data 3. 
 
 
Apart from the positive metabolic influence relationships examined above, the MIN also includes links 
of net negative metabolic influence.  Primarily, this type of relationship indicates possible competition 
for the same resources, which may lead to growth suppression of a microbial entity by another.  
Catenibacterium mitsuokai, Eubacterium rectale, and Veillonella atypica, which were all found to be 
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scarce in T2D (conversely, abundant in control), have net negative metabolic influence to many 
microbial entities found to be abundant in T2D (conversely, scarce in control).  For example, in the 
case of E. rectale, there is possible competition with L. delbrueckii and Lactobacillus fermentum for 
lactose consumption.  As an overview of the MIN from a male, mid-age, and normal weight cohort, 
Supplementary Data 3 provides descriptions of which metabolites determine each metabolic influence 
between pairs of microbial entities. 
   Taken together, our metabolic influence network of microbial entities portrays a roadmap of how 
chemical interactions come into effect for community members in the gut environment.  Given that 
microbial organisms in the gut can synthesize and export various chemical compounds, these 
microbial products can be seen as potential modulators of microbe-host interactions.  Although a 
thorough examination of all possible metabolite production is necessary toward understanding global 
microbe-host interactions, a more effective means would be to focus our efforts on the strongest and 
most relevant metabolic interactions.  For this purpose, we devised a computational method to 
pinpoint the chemical compounds and their associated microbial entities that compose the most 
representative interactions with the host (Methods; full details of our pipeline are presented in 
Supplementary Methods).  A list of these microbe-host relationships is provided in Supplementary 
Data 3. 
   In contrast to the entire spectrum of microbe-metabolite associations presented in Fig. 1, our T2D-
associated MIN illustrated in Fig. 4 offers a focused view of the most relevant microbe-microbe and 
microbe-host metabolic relationships.  These interactions could be interesting starting points for 
further interrogations on context-specific gut microbiota at the community level. 
 
Hierarchy of the microbial metabolic influence network 
In the influence networks shown in Fig. 4, the observation of hubs (i.e., microbial entities that exert a 
metabolic influence to a relatively high number of other microbial entities) prompted us to explore 
whether a hidden hierarchy of metabolic influence exists within the microbial communities.  To this 
end, we introduce the T2D-relevant, community metabolic influence of a microbial entity i (Φi), which 
can be estimated as 
∑ ∏
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where H(·) is the Heaviside step function, Wkm measures entity k’s direct metabolic influence on entity 
m (as previously defined), Pij denotes one of the shortest paths connecting entities i and j in the 
influence network, 〈·〉Pij is the average over the shortest paths, Δni/ni characterizes entity i’s relative 
abundance change from control to T2D subjects, and θΦ is a constant.  For the full details of Φi, 
including its formulation and case-dependent variations, see Methods and Supplementary Methods.  
Briefly, Φi denotes the cumulative number of community members towards which microbial entity i 
exerts a very positive or negative metabolic influence in either a direct or indirect way (an indirect way 
here means exerting the influence through other intermediate microbial members; see Methods).  For 
example, in our MIN, E. rectale was found to have a metabolic influence to 25 different microbial 
entities; hence its community metabolic influence Φi is quantified as 25.  Next, we measured the 
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community metabolic influences of all microbial entities in MIN (Fig. 5a).  In the MIN, we identified a 
set of highly interactive microbial entities, possibly acting as driving forces behind the global dynamics 
of their respective communities.  We call these entities the network influencers.  Among the total 
microbial entities, 17.6% were identified as network influencers. 
   Next, we examined some of the network influencers, and the metabolites underlying their 
community metabolic influence towards other microbial entities (Supplementary Data 3).  Influencers 
found to be abundant in T2D include Thermobifida fusca, A. muciniphila, and Pseudomonas 
aeruginosa.  T. fusca has a positive metabolic influence on non-influencers also abundant in T2D, by 
providing breakdown-products of cellulose and hemicellulose.  Likewise, A. muciniphila, through its 
participation in mucin degradation with other mucin-degraders, has a positive metabolic influence to 
sulfate-reducing bacteria in MIN, by providing access to sulfate (a mucin degradation product).  Qin et 
al. (whose data we used in this study) also found an increased abundance of A. muciniphila in 
patients with T2D12.  However, Everard et al. reported seemingly conflicting results, in which they 
observed a decrease in abundance of this mucin-degrader in fecal samples of diabetic mice33,34.  P. 
aeruginosa, a triglyceride degrader, can provide triglyceride degradation products to other microbial 
entities, indicating the role of dietary factors in this patient cohort.  Influencers abundant in control 
(alternatively, scarce in T2D) include E. rectale and Streptococcus salivarius.  E. rectale is a well-
known producer of butyrate, which has been demonstrated to be capable of improving T2D-
associated features35-37.  S. salivarius was found to have overall negative metabolic influences toward 
many microbial entities scarce in control, with competition for the consumption of sugars and B 
vitamins. 
   To gain insight into more general properties of network influencers, we conducted a global analysis 
of associations between influencers and compounds.  We found that the ability to degrade 
macromolecules (which in turn provides public goods) was the remarkably common metabolic feature 
among influencers.  The average proportion of macromolecule degraders among influencers (82.6%) 
was ~10 times higher than that among non-influencers (8.3%) (Fig. 5b), suggesting a prominent 
hallmark of network influencers. 
   Next, we identified microbes whose strains are recognized as human probiotics.  Among the entities 
of this MIN, there were 3 probiotic species, all of which were non-influencers (L. delbrueckii, L. 
fermentum, and Lactobacillus rhamnosus).  Although the general tendency of this result has yet to be 
examined, this observation gives an interesting perspective on the future design of probiotic 
regimens.  As an alternative to direct ingestion of multiple probiotic species, it may be advantageous 
to introduce influencers that could promote the growth of probiotic species already present among 
non-influencers.  Therefore, a thorough understanding of metabolic influence among microbial 
community members could aid therapeutic methods aiming to modify gut ecological composition. 
 
Commonly produced metabolites by MIN microbial entities 
Metabolites that often originate from microbial entities abundant in T2D may be indicative of how gut 
microbes, through their metabolism, play key roles in a specific disease context.  In this regard, we 
sought to identify the metabolites that are most commonly produced by microbial entities abundant in 
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either T2D or control.  Differences in these two sets of metabolites could provide insights into the 
metabolic processes of T2D-associated gut microbial ecosystems. 
  From all microbial entities differentially abundant in non-diabetic control, the top five commonly 
produced metabolites (in terms of the fraction of different entities that produce a given metabolite) 
were acetate (77.8%), CO2 (55.6%), lactate (55.6%), propionate (44.4%), and butyrate (44.4%) (Fig. 
5c).  Butyrate and propionate have been shown to exert multiple beneficial effects on host 
physiology38-41.  Some of these effects, which may contribute to protection from T2D, include intestinal 
glucose production (IGN, which helps prevent deregulation of glucose homeostasis and weight-gain)35, 
increase of energy expenditure36, and anti-inflammatory effects8,42.  In regards to lactate, it is 
noteworthy that certain strains of lactic acid bacteria have been reported to show anti-diabetic 
activities, possibly through a suppression of glucose absorption from the intestine43. 
  On the other hand, the top five metabolites (in terms of the fraction of different entities that produce a 
given metabolite) produced by microbial entities differentially abundant in T2D were acetate (25.6%), 
CO2 (21.4%), ammonia (NH3) (14.5%), hydrogen sulfide (H2S) (14.5%), and ethanol (10.3%) (Fig. 5d).  
Acetate and CO2 overlap with those in the aforementioned case of non-diabetic control.  For the 
remaining metabolites unique to T2D (i.e., NH3, H2S, and ethanol), their frequent appearance could 
suggest a distinct feature of the T2D-associated microbial community metabolism, although there is 
not yet conclusive evidence of their direct mechanistic links to T2D pathology.  It still warrants 
mentioning that NH3 and H2S, often the outcomes of protein fermentation processes by intestinal 
bacteria, are known to cause adverse health effects as carcinogenic and genotoxic agents44-47.  In the 
context of T2D pathology, it may be worthwhile to pursue these metabolites as part of future 
investigations into the mechanistic relationships between gut microbial metabolic processes and T2D. 
 
 
Figure 5. Characteristics of the metabolic influence network.  The community metabolic influence 
(Φi) of each microbial entity i was found for all nodes of the influence network (Fig. 4), and its 
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probability distribution is shown in (a).  This plot was used to identify microbial entities with relatively 
large metabolic influences; specifically, a transition point was chosen after a drop-off in the probability 
density of community influences (Methods).  Microbial species or groups with relatively large 
metabolic influence (shaded region) were designated as network influencers.  (b) Network influencers 
(denoted by ‘Infl’) have a higher proportion of macromolecule degraders than non-influencers 
(denoted by ‘n-Infl’), showing that macromolecule degradation is one of their key hallmarks.  (c) Top 
five most frequently produced metabolites by microbial entities differentially abundant in non-diabetic 
control: acetate (77.8%), CO2 (55.6%), lactate (55.6%), propionate (44.4%), and butyrate (44.4%).  
(d) Top five most frequently produced metabolites by microbial entities differentially abundant in T2D: 
acetate (25.6%), CO2 (21.4%), NH3 (14.5%), H2S (14.5%), and ethanol (10.3%).  Differences in these 
two sets of metabolites could suggest insights into metabolic processes associated with a T2D gut 
microbial ecosystem. 
 
 
Discussion 
 
To provide a global framework for understanding community metabolism within the human gut, we 
have presented in this study NJS16, a network architecture encompassing the myriad relationships 
among gut microbial species, host cells, and chemical compounds.  Specifically, our network shows 
how individual microbes interact with their chemical environment (via metabolite import, export, and 
macromolecule degradation), and thereby with other microbes (via resource competition, interspecies 
cross-feeding, and releasing macromolecule degradation products as public goods).  One significant 
aspect of our work is the inclusion of microbe-host metabolic interactions.  In this regard, our gut 
microbiota metabolite transport network can be investigated for identifying interaction pathways or 
modules that are associated with particular clinical conditions.  Because our network is mainly 
established upon literature annotations, it can serve as a useful data resource to those in the scientific 
community who wish to gain insight into microbe-microbe and microbe-host metabolic interactions 
relevant to a particular context.  Importantly, in order to stay scientifically correct and reliable, NJS16 
will need to be routinely revised and augmented. 
   In a patient population with a specific set of socio-demographic characteristics (i.e., male, mid-age, 
and normal weight), the microbial entities abundant or scarce in T2D, and the influence connections 
surrounding each microbial entity, were shown in a community-scale, metabolic influence network.  
The influence network suggests the presence of microbial entities that impose a relatively high degree 
of metabolic influence to other entities.  These influencers are essentially the hubs of the network, and 
could be considered as the main controllers of a hierarchical microbial community. 
   Apart from being consumed by microbial entities as part of an intricate cross-feeding web, 
metabolites that are produced and eventually exported into the microenvironment can directly affect 
host physiology through colonic absorption.  NH3 and H2S, which are known to cause detrimental 
effects to host health44-47, were found to be among the most frequently produced metabolites by 
microbial entities differentially abundant in T2D.  Although further investigation falls outside the scope 
of this study, it would be intriguing to ask whether these metabolites might be contributing factors or 
molecular signatures of T2D conditions.  However, focusing strictly on disease-associated metabolites 
may be limited in scope; ultimately, the origin of the exported metabolites (i.e., the microbial entities) 
must be considered to fully explain the complex narrative of how the gut microbiota contributes to a 
disease state.  To this end, our integrative framework can help elucidate metabolites that may be 
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linked to a particular disease condition, their microbial sources, and importantly, the infrastructure of 
the entire community influencing the metabolism and growth of those microbial sources. 
  Several limitations of our study should be noted when interpreting our results.  First, although the 
microbiome samples used in our study were metformin-naïve, and from a single ethnic background 
(Chinese), and our analysis was carefully conducted within a relatively homogeneous patient cohort, 
we cannot entirely exclude the possibility of other confounding factors.  Notably, the gut microbiota 
can be significantly altered by one’s dietary regimen30,48, the information of which was not available in 
the original dataset used in our study.  Eventually, replicating our analyses on more finely classified 
patient cohorts—while maintaining sufficient sample sizes—could improve control for these potential 
confounders.  Also, in our study, a lack of time-series microbiome data for the individuals makes it 
hard to establish any clear causal relationship between their gut microbiota and disease.  Availability 
of these time-series data would possibly lead to etiological discoveries.  Second, our gut microbiota 
metabolite transport network is currently limited to bacterial and archaeal species from a particular 
data source.  It needs to be expanded towards other species from different data sources, as well as 
towards other major phylogenies such as eukaryotes and viruses.  Recently, a taxonomic profiling 
method capable of strain-level identification of not only bacteria and archaea, but also eukaryotes and 
viruses, has been published49.  Clearly, one can apply such newer methods to update and expand the 
coverage of microorganisms in our network.  Third, almost all links between microbes and chemical 
compounds in our network were based upon literature annotations.  We believe that this network 
gives us a higher quality dataset than the ones obtained by purely bioinformatics predictions.  
However, our manual curation approach is not void of drawbacks: despite our best efforts, the 
manually-curated network may involve possible misinterpretations of the literature information.  Also, 
many of the experimental evidences considered were from in vitro studies, of which the results may 
not be straightforwardly translated into the in vivo events inside the gut.  Relatedly, oxygen-driven 
metabolic processes have long been thought to be irrelevant in the gut, but recent findings suggest 
the potential importance of oxygen for the gut microbiota composition50-52.  NJS16 does not have 
oxygen as an explicit metabolic compound, although Supplementary Data 2 provides information on 
individual species’ relationships with oxygen.  Furthermore, the links between microbes and 
compounds in our network reflect simple binary information of either the presence or absence of the 
corresponding associations, whereby the degree of activity of those transport reactions, or individual 
organisms’ growth requirements, are not yet distinguishable.  Substrate-dependent product formation, 
interdependency of different metabolic pathways, and end-product inhibition of cell growth have yet to 
be considered, and these would be better described by constraint-based genome-scale metabolic 
models.  Taken together, our purely connectivity-based network structure should be considered as a 
map of the metabolic potential of the microbial community, rather than of the actual state of 
metabolism itself.  In addition, the abundance of literature annotations is clearly biased towards well-
studied species and high-interest metabolites.  These issues regarding the limited completeness of 
our network can be addressed to varying degrees, as a broader range and richer depth of literature 
evidence becomes available.   
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   While we acknowledge these limitations and challenges, we perceive them as guiding routes and 
benchmarks for improving our network.  Each individual link in our network is from literature evidence 
(traceable literature references are provided in Supplementary Data 2), yet further experimental data 
are necessary to validate and update the global connectivity of the proposed network structure.  Thus, 
our work calls for the need to develop high-throughput, quantitative techniques for identifying and 
validating specific functions (e.g., import and export of metabolites, and release of public goods from 
macromolecule degradation) and microbial metabolic interactions (e.g., cross-feeding mechanisms 
and positive/negative metabolic influences) on a global scale, specifically within in vivo environments.  
Improvements in single-cell genomics and metabolomics strategies, in culturing techniques for 
previously uncultured microbes53,54, and in platforms for in vivo high-throughput screenings will 
undoubtedly accelerate this process.  The advent of such technologies could confirm or update our 
findings, as well as push forward and establish general concepts and theories of ecological systems 
biology. 
   Clearly, a comprehensive understanding of the metabolic relationships between gut microbes, and 
of how those relationships are intertwined with host physiology, is essential for the development of 
microbiota-based treatments for disease55,56.  We see our work as an important step towards this 
direction, by providing an in silico platform for the rational design of microbial communities to benefit 
host health.  Specifically, our network could be utilized to generate computational models for 
predicting the outcome of species-level perturbations on a microbial community and its host 
environment.  Promising approaches in this front can be constraint-based methods22,24,57-59 and kinetic 
modeling23,60-63.  In this direction, we expect our own microbial ecological networks to help in the 
development of personalized clinical strategies.  Beyond metabolic interactions focused on by this 
study, considering quorum sensing molecules, virulence factors, and genes for metabolic traits and 
transporters passed along in horizontal gene transfer64,65 would be another interesting avenue to 
pursue using network-based approaches. 
   Ultimately, gut microbiome analyses will evolve beyond descriptive, profiling investigations toward 
more hypothesis-driven, mechanism-focused studies.  However, progress in this direction will be 
contingent upon the maturation of our general understanding of the global inner workings of a 
microbial community.  We envision that microbiome studies adopting systems biology approaches 
and multi-omics data integration66 will be at the forefront of unraveling the complexity of the gut 
microbiota, as well as realizing its potential therapeutic applications. 
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Methods 
 
Collection of microbiome data and taxonomic profiling 
Raw metagenomic sequencing data from fecal samples of 363 Chinese individuals (T2D and non-
diabetic controls) were downloaded from the NCBI Sequence Read Archive (SRA) database 
(SRA045646 and SRA050230).  Microbiome samples with missing patient metadata, of low read 
count after alignment (<100,000 reads), or highly deviated from the majority of the samples in their 
clustering results were removed from our study (Supplementary Data 1).  The taxonomic profiling 
software that ran on these microbiome data was MetaPhlAn, which uses clade-specific marker 
sequences to identify microbial taxa (with species-level resolution) and their relative abundances from 
a metagenomic sample67.  The marker gene catalog used in MetaPhlAn was from microbial genomes 
from the Integrated Microbial Genomes (IMG) system (July 2011).  The MetaPhlAn software 
compares each metagenomic read from a sample to this marker catalog in order to identify high-
confidence matches.  When using MetaPhlAn, the default “rel_ab” parameter options were selected.  
For all of our samples, using MetaPhlAn gave rise to a total of 1,219 identified bacterial and archaeal 
species, which cover ~70% of all the species from a unified gut microbiome dataset with additional 
data sources (HMP reference genomes, HMSMCP - Shotgun MetaPHlAn Community Profiling, and 
GutMeta DownLoad Center; accessed August 2016). 
 
Collection of metabolic information for NJS16 construction 
Metabolic information primarily used in this study was experimental evidence of metabolite transport 
or macromolecule degradation reported in literature.  This information is dispersed across numerous 
scientific journal articles and textbooks.  Therefore, a careful read of hundreds of these sources 
(Supplementary Data 2) was done to discern which annotations were experimentally verified, from 
those that were predicted solely based on automated bioinformatics algorithms.  The small-molecule 
metabolites considered in our work were mostly primary metabolites, i.e., nutrients involved in 
microbial growth, development, or reproduction, or byproducts of those metabolic processes.  Most 
chemical derivatives of those primary metabolites, as well as many secondary metabolites, e.g., 
antimicrobial toxins, oligopeptides, and quorum-sensing molecules, were excluded from our study.  In 
addition, literature sources that report the mRNA or protein expression for metabolic-byproduct-
producing enzymes, or for metabolite-specific transporters, were considered.  Small metabolites that 
can diffuse through cell walls (e.g., H2 and CO2), thereby not requiring transporter proteins, were also 
considered, as long as they serve as primary substrates and/or products of cellular metabolism.  
Furthermore, if a given microorganism or human cell type has a published, manually-curated genome-
scale metabolic model, transport reactions from the model were considered for that organism or cell 
type.  Importantly, all annotated metabolite transport or macromolecule degradation processes for 
different strains of the same species were unified as collective features of that particular species.  
Because degradation of a given macromolecule is generally conducted by multiple species in the gut, 
the corresponding degradation products (Supplementary Data 2) were considered as indirect export 
products of all species involved in that macromolecule degradation.   
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   In NJS16, one set of nodes corresponds to organisms in the gut microbiota community (i.e., 
microbial species and host cells), whereas the other set corresponds to chemical compounds (i.e., 
small-molecule metabolites or macromolecules).  The microbes in our network were connected to the 
metabolites they can import from, and/or export to, their microenvironment, or to the macromolecules 
they can degrade in their extracellular space.  Taken together, NJS16 is a comprehensive, primarily 
literature-curated, microbiota interaction map that accounts for 567 bacterial and archaeal species in 
the large intestine, 3 human cell types metabolically interacting with those colonic microbes, and 244 
chemical compounds—all interconnected via 4,483 small-molecule metabolite transport or 
macromolecule degradation processes.  To facilitate visual exploration, Supplementary Data 4 
provides NJS16 in graph-editor accessible, markup language file format. 
 
Identification of patient-cohort specific microbial entities 
All microbiome samples were categorized into sub-population cohorts based on each subject’s 
gender (male/female), age-range [young (age < 45yrs), mid-age (45yrs ≤ age < 65yrs), and old-age 
(65yrs ≤ age), as defined by the United States Census Bureau], and BMI-range [underweight (BMI < 
18.5), normal weight (18.5 ≤ BMI < 25), and overweight (25 ≤ BMI)].  Among our T2D samples, we 
used only those from metformin-untreated patients, information on which was provided by a recent 
study on metformin-confounding effects on the gut microbiota32.  Among all eighteen possible cohorts 
for both T2D patients and non-diabetic controls, the male, mid-age, and normal weight cohort (control 
n = 21; T2D n = 11) was selected for detailed analyses based on its having the largest sample size 
among all cohorts, as well as having comparable sample numbers in both phenotypes (control and 
T2D).  Microbial species differentially abundant or scarce in T2D patients (compared to non-diabetic 
control subjects) were identified by the Wilcoxon rank-sum test, and false discovery rate correction 
was used for multiple testing (FDR < 0.1; Supplementary Methods).  To identify differentially abundant 
or scarce groups (genus or metabolic clique), the sum of all relative abundances of microbial species 
in a particular group was obtained to represent the relative abundance of the group, then followed by 
the Wilcoxon rank-sum test and false discovery rate correction (FDR < 0.1; Supplementary Methods).  
The microbial entities (species, genera, and metabolic cliques) found to be differentially abundant or 
scarce in T2D were selected for further pruning to identify the most representative microbial entities 
(Supplementary Methods). 
 
Construction of a microbial metabolic influence network 
The bipartite network of microbial species and metabolic compounds (NJS16) can be utilized as a 
global template for constructing a context-specific network.  For the male, mid-age, and normal weight 
cohort, NJS16 was converted into a unipartite network of microbial entities (species, genera, and 
metabolic cliques) differentially abundant or scarce in T2D compared to non-diabetic control.  This 
network is called herein a microbial metabolic influence network.  The conceptual framework for 
constructing this network is as follows: in complex, microbial ecosystems, a microbial entity can 
provide nutrients to another entity via interspecies cross-feeding of metabolic byproducts and/or 
release of macromolecule degradation products.  This positive impact may potentially promote 
microbial growth.  In contrast, a microbial entity can limit the access to nutrients of another entity via 
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competition for the same metabolites.  This negative impact may potentially inhibit microbial growth.  
Based on the combination of these positive and negative effects, the net metabolic influence of a 
microbial entity i on another entity j (Wij) can be calculated.  To quantify Wij, the potential metabolic 
influence of one microbial species on another microbial species needs to be estimated.  For a pair of 
species i and j, an increase in species i’s abundance may contribute to an increase or decrease in 
species j’s growth (the use of either the growth rate or the abundance does not much affect the 
following argument).  Species i’s influence on species j’s growth is expressed by 𝑊𝑖𝑖 =  (𝜕𝜇𝑗)/𝜇𝑗 (𝜕𝑛𝑖)/𝑛𝑖 , where 
μj is species j’s growth rate, and ni is species i’s abundance. Wij > 0 (< 0) indicates the positive 
(negative) metabolic influence that species i is promotive (inhibitive) for species j’s growth.  In more 
detail, 𝑊𝑖𝑖 =  (𝜕𝜇𝑗)/𝜇𝑗 (𝜕𝑛𝑖)/𝑛𝑖 = 𝑛𝑖𝜇𝑗 ∙ �𝜕𝜇𝑗𝜕𝑛𝑖� = 𝑛𝑖𝜇𝑗 ∙ ∑ 𝜕𝜇𝑗𝜕𝑧𝑘𝑗 𝜕𝑧𝑘𝑗𝜕𝑛𝑖𝑘 , where k denotes each metabolite imported by 
species j, and zkj is the rate of metabolite k consumed by species j per unit abundance.  By assuming 
proper forms of μj and zkj, as a function of {zkj} and that of {ni}, respectively (Supplementary Methods), 
Wij can be written as: 
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where gikp(c) =1 if species i produces (consumes) metabolite k, or otherwise, gikp(c) =0, and α is a 
constant.  If species i degrades macromolecules whose breakdown products are consumed by 
species j, Wij contains additional terms that are described in Supplementary Methods.  Further details 
of Wij, including its formulation, the incorporation of macromolecule degradation, and the 
determination of α, are presented in Supplementary Methods. 
   Next, we found that a potential metabolic influence of one microbial group G on another microbial 
group Γ (each group is either a genus or metabolic clique) is the weighted sum of Wlq (species l in 
group G and species q in group Γ) with each weight being proportional to species q’s abundance 
(Supplementary Methods).  Consequently, a metabolic influence of one microbial entity on another 
microbial entity can be calculated for every pair-wise case.  For every pair of differentially abundant or 
scarce entities i and j in T2D, a directed link with weight Wij from entity i to entity j (and vice versa) 
was assigned.  Among these links, only the links that account for actual microbial abundance changes 
between control and T2D subjects (Supplementary Methods) were considered. 
   In addition to microbe-microbe interactions, microbe-host interactions were examined, and the 
representative interactions in the patient cohort were identified, as follows: among metabolic cliques 
that are differentially abundant in T2D or in control, those that could either directly influence, or are 
directly influenced by, host cells were initially selected.  These metabolic cliques can be regarded as 
proxies for enriched chemical compounds in T2D or in control.  Then, all microbial entities (of the 
corresponding metabolic influence network) with commonalties to the previously selected cliques in 
regards to relevant phenotypes (i.e., abundant in T2D or in control), as well as metabolic capability 
(i.e., consumption, production, or degradation of a chemical compound), were selected.  These 
microbial entities were recognized as putative candidates for having an important metabolic 
relationship with the host.  Full details of our methods are presented in Supplementary Methods. 
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Identification of network influencers 
In a microbial metabolic influence network, a microbial entity i can exert a metabolic influence on 
another microbial entity j if they are directly connected to each other.  Even when they do not have a 
direct connection, entity i may indirectly exert a metabolic influence on entity j, if other entities located 
between the two can transfer entity i’s influence to entity j.  Taking into account both of these direct 
and indirect effects, the quantity ΦijPij, which measures entity i’s influence on entity j along the shortest 
path Pij between the two entities, can be defined (we only consider the influences that are relevant to 
the host phenotype difference between T2D and control).  Because there can be either single or 
multiple shortest paths, Φij ≡ 〈ΦijPij〉Pij, where 〈·〉Pij is the average over the shortest paths.  Φij serves as 
an estimate of entity i’s overall metabolic influence on entity j. 
   Next, the community-level metabolic influence of entity i (Φi) is defined as the number of entity j’s 
that satisfy |Φi| ≥ θΦ (θΦ is a constant determined in Supplementary Methods).  By formulating ΦijPij as 
a function of {Wkm: k, m ∈ Pij} and microbial abundances (Wkm denotes entity k’s direct metabolic 
influence on entity m, as previously described), Φi can be written as: 
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where H(·) is the Heaviside step function, and Δni/ni characterizes entity i’s relative abundance 
change from control to T2D subjects.  For full details of Φi, including its formulation and case-
dependent variation, see Supplementary Methods. 
   Lastly, the network influencers, which are microbial entities with distinctively large Φi’s, were 
identified as follows: we identified a transition point of Φi from the probability distribution of Φi (Fig. 
5a), which distinguishes one group of microbial entities (shaded area in Fig. 5a) from the other in their 
Φi’s, and we use this transition point of Φi as the lower bound of the influencers’ Φi. 
 
Data availability 
All relevant data are available in the paper and Supplementary Information.  NJS16 (Supplementary 
Data 2) is also available in the Dryad Digital Repository68.  Codes are available in Supplementary 
Software. 
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